From Zero to Launch
Best practices for successfully launching your first commercial product
Contents

Foundation for Commercial Launch Success ................................................................. 3
  Market Readiness ........................................................................................................... 5
  Operational Requirements .......................................................................................... 5
    Medical Information Development .......................................................................... 6
    Customer Data, Territory Alignments, and Prospect Database .................................. 6
    Commercial Content ............................................................................................... 8
    Third-Party Integrations ......................................................................................... 8
  Successful Launch Execution ..................................................................................... 9

Customer Success ........................................................................................................ 10
  Medac Pharma, Inc. Fast-tracks Successful U.S. Launch of Rasuvo™
  with Veeva Commercial Cloud ............................................................................... 10
  Get Your Own Custom Launch Roadmap ................................................................. 10
Research indicates that 81% of future drug sales performance is determined by actions sponsors take during clinical development, early commercialization, and product launch. The first six months post-launch are considered to be vital to the long-term commercial success of a drug. During this critical period, pre-commercial companies have the opportunity to outperform established competitors through agile, intelligent customer engagement.

Sponsors introducing their first product should plan and execute a best practices-based launch strategy, building a scalable commercial program tailored to their organization’s unique strategy. This helps proactively address two of the most common commercialization challenges:

1. Overcoming resource constraints that prevent the implementation of all necessary operational requirements, and;
2. Initiating market readiness activities earlier in the development process, rather than the highly condensed timelines typically associated with a first-time product launch.

Companies that successfully implement a defined launch methodology are more likely to attain their revenue goals. They have a unique opportunity to outperform the competition. According to a McKinsey & Company report, “about two-thirds of new drugs fail to meet pre-launch consensus sales expectations for their first year on the market.” This same study finds that a majority of these drugs continue to underperform even three years post-launch, costing the industry hundreds of millions of dollars in lost revenue.

The life sciences industry has a unique opportunity to change this paradigm and generate faster time to peak revenue. Pre-commercial companies can place the customer at the center of their commercial strategy using coordinated, intelligent engagement. As technology is no longer a barrier to delivering educational or scientific content, it is critical to connect and engage with healthcare professionals (HCPs) and institutional decision makers. Insights generated through customer interactions enable the organization to accurately align with a customers’ specific scientific need. Pre-commercial companies can leverage this data-driven process to deliver new content to HCPs and other stakeholders in the way they want to consume information.

Foundation for Commercial Launch Success

Companies in this pre-commercial phase encounter distinct challenges as they introduce their first drug to market. They often compete against established life sciences companies with sophisticated go-to-market strategies and established provider relationships. Further complicating the launch, access to physicians has declined from 78% in 2009 to a record low of 47% in 2015. Pre-commercial companies are more likely to succeed if they follow a customized commercialization program. The “Foundation for Commercial Launch Success” is a roadmap based on best practices that guides sponsors introducing their first product to market (Figure 1). It outlines a proven launch methodology, leveraging Veeva’s experience helping hundreds of life sciences companies around the world commercialize medicines.

The product launch consists of a series of well-planned and synchronized activities, executed many months in advance of the expected product approval date. Giving launch teams sufficient time and resources to prepare for product introduction is critical to success. Commercial planning activities should therefore begin as early as Phase IIb trials, as the data indicates that clinical endpoints will be met. As the study progresses, the launch program will also increase in complexity.

This tailored commercialization program helps sponsors develop a customer engagement program that is agile, efficient, and intelligent. The launch roadmap must enable both medical and commercial functions to align and collaborate. It is organized across two concurrent dimensions: 1) market readiness activities, and 2) operational requirements.

---

FIGURE 1

Foundation for Commercial Launch Success

MONTHS UNTIL LAUNCH

<table>
<thead>
<tr>
<th>PHASE IIB TRIALS</th>
<th>PHASE III TRIALS</th>
<th>REGULATORY PREP</th>
<th>REGULATORY REVIEW</th>
<th>LAUNCH READINESS</th>
<th>COMMERCIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA SUBMISSION</td>
<td>NDA APPROVAL</td>
<td>LAUNCH</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OPERATIONAL REQUIREMENTS</th>
<th>GO-TO-MARKET ACTIVITIES</th>
<th>KOL management and visibility</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Derive insights and quantifiable value</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coordinated engagement across channels: Email, online meetings, virtual events, web, face-to-face</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HCP engagement</td>
</tr>
<tr>
<td></td>
<td>Medical / scientific (KOL) engagement, communication and publications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>KOL management and visibility</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Derive insights and quantifiable value</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2nd-tier KOL identification, profiling and planning</td>
<td></td>
</tr>
<tr>
<td>Speaker programs</td>
<td>Plan, budget, track speaker meetings</td>
<td></td>
</tr>
<tr>
<td>HCP, HCO and affiliations data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Customer master, product master</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transparency, reporting, digital engagement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Territory alignment design and planning</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alignment execution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compliant review/approval of promotional materials</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution across communication channels</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digital asset management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Content re-use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Customer database build, segmentation and targeting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analytics and BI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Call planning, execution and recording</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3rd party system integrations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Timelines are general estimate only and can significantly vary in length.
Market Readiness

Key opinion leaders (KOLs) validate and disseminate emerging scientific information with the broader medical community, significantly impacting established patient care practices. Successfully identifying, engaging, and establishing credibility with the right KOLs is one of the most important aspects of a new product launch.

KOL engagement should begin during Phase II, focusing on the nature of the intervention and its potential to impact patient outcomes. Organizations can reinforce the validity of the clinical data through participation in congresses, publications, and medical symposia. Upon reaching the Phase II endpoint, newly generated scientific data can be used to develop peer-reviewed, evidence-based, clinical information. Disease state education programs may be defined, including planning, budgeting, and tracking of meetings. Over time, the nature of the discussions must evolve from disease state awareness to education around clinical results and, eventually, therapeutic outcomes.

As the clinical trial progresses, sponsors can identify, profile, and plan their outreach to more KOLs. Engagement from medical affairs teams provides greater visibility, derives medical insights from KOLs, and helps quantify the economic value of the drug.

In addition, access to payers—insurance plans, pharmacy benefits managers, government, and employee networks—is crucial to making the treatment available to patients. Market access field teams must leverage KOL-derived insights to prove the clinical efficacy and health-economic value of the new product relative to other interventions in the market.

While KOL relationships may be established early, commercial HCP engagement can only begin as the drug receives regulatory approval. Care must be taken to avoid inadvertent pre-label promotions. Representatives may engage in coordinated provider engagement across personal and digital channels to ensure delivery of relevant disease state education to the broadest group possible. This allows the commercial organization to better understand their targets’ communication channel preference.
Operational Requirements

Concurrently, sponsors must also ensure that they are operationally prepared to support their go-to-market program. The goal is to establish a business environment that fosters agile, efficient, and intelligent customer engagement. Even in this early pre-commercial stage, the company should aim to develop business processes, and a supporting commercial infrastructure, that support the organizations expected growth. Special consideration should be given to ensure that it can also be leveraged for potential future product introductions.

Medical Information Development

These operational programs should also be implemented well in advance of the product launch. To properly educate KOLs, scientific materials must be developed approximately 24 months prior to expected product launch. As the trial enters Phase III, the medical science liaison (MSL) and medical information teams should already be fully enabled. Due to the high-profile nature of clinical trials, especially in rare diseases or oncology, medical launch teams must anticipate the scientific needs of the treating community. Companies may expect to act on requests for data and information as soon as it has been presented publicly. This can be achieved if Medical Affairs is given the ability to develop, review, and approve a broad variety of medical content, such clinical results, mechanism of action studies, and Health Economics and Outcomes Research (HEOR). Medical affairs must respect the compliant nature of data requests while still aligning to the customer’s channel preferences and learning objectives.

Benefits of an Integrated Commercial Cloud Deployment

90% Efficient
Faster data change requests

96% Agile
Faster deployment

6x Smarter
Increase in sales performance

Source
1. Veeva study: Veeva OpenData resolves DCRs in under one day on avg., compared to 10 days avg. for legacy data vendor, a 90% reduction.
2. Reduced time to implement full Commercial Cloud at a pre-commercial company dropped from typical two years to just 8 – 14 weeks.
3. Veeva study: Avg. click-through rate for Veeva CRM Approved Email is six times higher than industry average.
Customer Data, Territory Alignments, and Prospect Database

The organization’s ability to efficiently and effectively manage the flow of information across the enterprise is a key enabler to the success of the launch. Therefore, organizations should consider deployment of their analytics and business intelligence platforms in parallel to development of scientific materials. Market assessment is the first, and most important, analytical study, typically initiated towards the end of Phase II. It delivers key insights and guidance in the development of the overall brand strategy as well as product messaging for both launch and ongoing promotion. Upon completion, commercial teams will be armed with the size of the patient population, the scope of treatment options, and a forecast of product profitability.

Accurate and current customer data, analyzed via scalable and repeatable processes, will provide critical insights on the launch. These will guide stakeholders to help optimize commercial performance using a 360-degree view of customer activity. Key components that will need to be implemented are the master data management platform—including both customer and product master—the data warehouse, as well as statistical modeling and reporting tools.

The most important aspects of the analytical environment are the creation and maintenance of an optimally sized and structured sales force, followed by the alignment of sales representatives, and assignment of HCP targets to territories. As a best practice, these assignments should be considered within the overall information management strategy to ensure that they are effectively shared with downstream analytics and incentive compensation systems. An integrated territory master, similar in nature to a master data management capability, provides the ability to archive historic alignments for analytical purposes, current alignments for execution, and future alignments for scenario planning.

Best-in-class territory alignment systems can be particularly effective at smaller life sciences organizations. These organizations often rely on legacy territory alignment processes that require multiple weeks to conduct a major alignment, limiting their ability to rapidly react to changes in the market. In real-world instances, an integrated alignment solution achieves a five to ten-fold reduction in process steps—translating to a 50% decrease in resources necessary to conduct alignments5—as well as decreasing the time required for major alignments by 75% or more.6 In a highly competitive business environment, these companies are able achieve significant cost savings while also supporting revenue growth through greater business agility.

---

5 Real-world results achieved by small European-based pharmaceutical company (2017)
6 Real-world results achieved by small US-based pharmaceutical company, presented at 2017 Veeva Commercial Summit
Customer Success: Commercial Content and Digital Asset Management Deliver Speed to Market, Control, and Cost Savings

**Speed to Market**
- 57% reduction in review cycle times\(^1\)
- 25% reduction in time spent on compliance procedures\(^1\)
- 2x faster content to market\(^2\)

**Compliant**
- Instant content withdrawal
- Centrally controlled

**Savings**
- 6-month ROI attainment\(^{1,2}\)
- 40% marketing budget savings from content reuse\(^1\)
- 50% reduction in training effort\(^2\)

**Sources**
1. Veeva study, average across customers
2. Results reported by top global pharma

As the new therapeutic progresses closer towards NDA submission, the commercial team’s activities also accelerate. A prospect database should include reliable information on target HCPs, healthcare organizations (HCOs), and their respective affiliation data. Sample eligibility verifications can sometimes take anywhere from two to four weeks. Accurate and current target customer data solves this problem through immediate eligibility confirmation. While important to all pre-commercial companies, this is particularly vital for those focusing on oncology, developing specialty therapeutics, or orphan drugs.

> "Veeva Commercial Cloud…allows us to make the customer central to everything we do. All customer touch points are channeled through Veeva Commercial Cloud—making it an integral part of our customer engagement strategy."

—Terri Shoemaker President and CEO, Medac Pharma
Commercial Content

As the various operational aspects coalesce around the coming launch, commercial teams will need to consider their promotional strategy. The rapid creation and management of promotional assets for HCPs is a key competitive advantage for pre-commercial companies. Studies indicate that 72% of doctors demand more channels. Increased content speed to market, delivered in the prescriber’s preferred channel, is vital to market adoption. Resource-constrained organizations can overcome the expense and complexity of rapid content development through fast, compliant, and insights-driven management of promotional assets. It can be achieved if the process is administered through a central content management platform, enabling collaborative and efficient management of the content lifecycle through approval, distribution, reuse, and withdrawal. This integrated view into the digital supply chain helps optimize the entire content management effort. As a result, companies bring new content to market up to two times faster while also saving more than 40% of the marketing budget through better content reuse.

Third-Party Integrations

In order to enable the most complete customer view possible, sponsors should proactively plan for integrations between their CRM and various third-party systems. This is an important part of the pre-launch strategy, though it is frequently overlooked until after product launch. Since no one single vendor can provide all necessary capabilities for the entire industry, the core CRM technology must be open and interoperable. This allows it to connect with the broadest possible ecosystem of partner technologies. Some of the most common integrations to consider are fulfillment and sample accountability, patient portals, expense management, analytics, and a specialty pharmacy distribution hub.

Successful Launch Execution

For maximum commercial impact, pre-commercial companies can implement a defined launch path based on established best practices that allows for flexibility to adjust as circumstances require. Technology must be an enabler rather than a barrier to the overall launch success. Agile life sciences companies rely on a proven and configurable cloud-based system rather than on cumbersome customizations or unproven technologies. Commercial teams can experiment with innovations in both business processes and technology. They are able to easily collect data (field feedback on territory alignments, provider engagement data, content use and effectiveness, etc.), draw actionable insights, and rapidly refine their go-to-market strategy.

Not every sponsor will need to implement every component of the roadmap, and each company will prioritize specific aspects of it based on their own, unique situation. The ultimate outcome is that sponsors have the opportunity to proactively build a commercial program that maximizes the chance of a successful product launch.

---

7 What Physicians Want,' Publicis Touchpoint Solutions
Customer Success

Medac Pharma, Inc. Fast-tracks Successful U.S. Launch of Rasuvo™ with Veeva Commercial Cloud

After filing the 505(b)2 application for Rasuvo® (methotrexate injection) with the FDA, Medac Pharma needed to quickly build a commercial foundation for product sales and marketing. Four months later, Medac Pharma was ready for business with Veeva Commercial Cloud and fully prepared to take its first product to market.

Starting with a blank slate, Medac Pharma had the rare opportunity to establish the right technology foundation from the start to maximize commercial success. The company sought a complete solution that would meet the needs of sales, marketing, and medical teams and align the entire organization around the customer. “With Veeva Commercial Cloud, we gained the full breadth of commercial capabilities in one complete solution to enable fully coordinated customer engagement across channels. And with Veeva, we were able to meet our aggressive four-month deadline and go live successfully,” said Glenn Tate, Medac Pharma’s Senior Director of IT.

“I knew that I wanted a system that was proven, fit, and didn’t require extensive customization. It needed to be streamlined, too, without pieced-together point solutions underpinning Medac Pharma’s commercial operation,” explained Tate. “Veeva Commercial Cloud fulfills all of our needs, including important functions like sample validation. Its flexible, multitenant architecture enables ongoing innovation and grows with us as we expand into potential new areas such as oncology.”

Medac Pharma President and CEO Terri Shoemaker noted, “Veeva Commercial Cloud provides all of the critical elements of a successful pharma commercial operation, seamlessly connected in one solution. It allows us to make the customer central to everything we do. All customer touch points are channeled through Veeva Commercial Cloud – making it an integral part of our customer engagement strategy.”

“With Veeva Commercial Cloud, all of our teams see the full history of customer interactions whether through an email, online detail, phone call, or face to face. There’s a continuous feedback loop about where the doctor is in the sales process, which allows for rich insights aggregated across every step of the customer journey and informed future engagement,” said Mike Henrick, associate director, of sales operations for Medac Pharma. “We’ve also gained digital channels to communicate with customers on their terms, allowing us to reach more HCPs efficiently—a critical advantage for a growing organization like ours.”

Get Your Own Custom Launch Roadmap

The Veeva Commercial Cloud delivered the competitive advantage Medac Pharma needed to successfully launch Rasuvo. Please contact our commercialization experts for a complimentary workshop to help develop your own customized launch roadmap.
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 550 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit www.veeva.com.

Veeva Systems
Global Headquarters
Pleasanton, California, USA
4280 Hacienda Drive
Pleasanton, California 94588
+1 925 452 6500 | veeva.com/contact-us | veeva.com

Disclaimer:
Veeva’s “Foundation for Commercial Launch Success” guide has been developed based on direct experience gained helping hundreds of companies commercialize their products. It is intended as a general best practices guide and may not apply to every organization or medical intervention. Each pre-commercialization effort has unique timelines and requirements that affect the details of the actual product launch process.